Perry C. Siatis - 02 Feb 2024 Form 4 Insider Report for AbbVie Inc. (ABBV)

Signature
T.O. Odutayo, attorney-in-fact for Perry C. Siatis
Issuer symbol
ABBV
Transactions as of
02 Feb 2024
Net transactions value
-$496,230
Form type
4
Filing time
06 Feb 2024, 17:00:10 UTC
Previous filing
05 Apr 2023
Next filing
20 Feb 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABBV Common Stock, $0.01 par value Award $421,912 +2,919 +28% $144.54 13,296 02 Feb 2024 Direct
transaction ABBV Common Stock, $0.01 par value Disposed to Issuer $496,230 -2,919 -22% $170.00 10,377 02 Feb 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABBV Option (Right to buy) Options Exercise $421,912 -2,919 -33% $144.54 5,837 02 Feb 2024 Common Stock 2,919 $144.54 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This sale was executed pursuant to a Rule 10b5-1 plan that was entered into by the Reporting Person on February 14, 2023.
F2 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.